Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52)

Author:Clarkson, Kristen   Utsugisawa, Kimiaki   Benatar, Michael   Ciafaloni, Emma   Leite, Maria   Vissing, John   Tang, Fengming   Peer, Cody J.   Cheng, Sue   Howard, James   Nowak, Richard   

Session Name:S14: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S14.009  

Author Institution:Amgen Inc., CA  Hanamaki General Hospital, Hanamaki, Japan  University of Miami, Miami, FL  University of Rochester Medical Center, Rochester, NY  Nuffield Department of Clinical Neurosciences - University of Oxford, Oxford, United Kingdom  University of Copenhagen, Copenhagen, Denmark  The University of North Carolina, Dept of Neurology, Chapel Hill, NC  Yale University School of Medicine, New Haven, CT  

Inebilizumab for Treatment of NMOSD in a Real-world Cohort: Analysis from the SPHERES Registry

Author:Levy, Michael   Cavida, Dustin   Patterson, Kristina   Park, Jenny   Wani, Rajvi J.   Meyers, Andrea   Middaugh, Nicole   Choi, C. Jean   Gurrola, Marie   Bennett, Jeffrey   

Session Name:P3: Autoimmune Neurology: NMOSD/MOGAD 3  

Topic:Autoimmune Neurology  

Program Number:P3.012  

Author Institution:Massachusetts General Hospital/Harvard Medical School, Boston, MA  Amgen Inc., Thousand Oaks, CA  Amgen Inc. , Thousand Oaks, CA  Amgen Inc., CA  Amgen, Inc., CA  Thermo Fisher Scientific, MA  University of Colorado School of Medicine, Aurora, CO